GlassScriptPhysician profile
Michael Wieland
NPI 1861019945
$4,484.45
in general payments reported to CMS, 2019-2025
34 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,248 · 2023: $1,280 · 2024: $544 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.70 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $556.36 | 2021-2025 | Evenity, Tepezza, Repatha |
| Dexcom, INC. | $501.29 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $465.10 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $417.70 | 2021-2025 | Farxiga |
| Lilly USA, LLC | $394.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $383.31 | 2022-2023 | |
| Abbvie INC. | $159.55 | 2021-2025 | |
| Medtronic, INC. | $158.35 | 2021-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $140.36 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $135.77 | 2021-2025 | |
| Antares Pharma, INC. | $133.87 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Mannkind Corporation | $116.59 | 2022-2023 | Afrezza |
| Horizon Therapeutics Plc | $112.05 | 2022-2023 | Tepezza |
| Corcept Therapeutics | $108.55 | 2022-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $71.50 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.65 | 2021-2022 | |
| Bigfoot Biomedical INC | $57.78 | 2022-2023 | Unity Diabetes Management System |
| Abbott Laboratories | $56.24 | 2022-2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $47.63 | 2021-2022 | |
| Sequel Med Tech, LLC | $47.19 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.81 | 2023 | Jardiance, Tradjenta, Glyxambi |
| Almatica Pharma LLC | $43.88 | 2025 | Teriparatide |
| Insulet Corporation | $36.00 | 2022-2024 | Omnipod |
| Amryt Pharma Holdings LTD | $33.88 | 2022-2023 | Mycapssa |
| Averitas Pharma INC. | $28.58 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $27.57 | 2024 | |
| Alexion Pharmaceuticals, INC. | $24.69 | 2023 | Strensiq |
| Sandoz INC. | $22.33 | 2025 | Hyrimoz |
| Madrigal Pharmaceuticals | $19.25 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $18.35 | 2023 | Nexletol |
| Ascendis Pharma Endocrinology INC | $16.27 | 2025 | Yorvipath |
| Halozyme INC | $15.50 | 2023 | |
| Ibsa Pharma INC. | $14.74 | 2021 | |
| Radius Health, INC. | $13.63 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wieland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.